Demonisation of rosiglitazoneBMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d2571 (Published 21 April 2011) Cite this as: BMJ 2011;342:d2571
- Vernon J Heazlewood, senior staff specialist
- 1Queensland Health Metro North HSD, Caboolture Hospital, Caboolture, QLD 4510, Australia
Loke and colleagues consider the idea that pioglitazone yields cardiovascular benefits, but readily dismiss it.1 This is an equally plausible explanation of the analysis, however, given that it compares pioglitazone and rosiglitazone rather than placebo or control treatment. There is moderate …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial